Mirum’s Atebrioz reduces bone lesion volume in FOP trial in children aged 6 to under 12

• Mirum Pharmaceuticals reported positive pivotal PROGRESS trial results for Atebrioz in children aged 6 to under 12 with fibrodysplasia ossificans progressiva.
• Treatment reduced abnormal bone formation versus placebo, improved joint mobility and prevented new lesions during the 24-week study.
• A supplemental application planned for the first half of 2027 would seek to expand treatment to this younger age group.
• Atebrioz received FDA approval in September 2026 for adults and children aged 12 and older with the disease.
• Full results, showing no new safety signals, will be presented at an upcoming medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026062788) on October 26, 2026, and is solely responsible for the information contained therein.